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A B S T R A C T
HIV and tuberculosis (TB) are leading global causes of mortality and morbidity. Highly active
antiretroviral therapy (HAART) is often initiated in patients being treated for TB. The immune recovery
associated with HAART results in dramatic clinical beneﬁts, but this restoration of immunity may result
in immunopathological reactions. The immune reconstitution inﬂammatory syndrome can result in
fever, nodal enlargement, and worsening pulmonary inﬁltrates observed on a chest radiograph, with or
without recurrent respiratory symptoms. Several other manifestations have also been described. As a
consequence, the use of HAART might not be appropriate during the ﬁrst weeks of anti-TB therapy in
HIV-infected patients. In this review, we summarize the incidence, clinical presentations, and potential
mechanisms of these conditions and we describe therapeutic methods.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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HIV and tuberculosis (TB) are leading global causes of mortality
andmorbidity.1 In 2000, 7–12% of the estimated 8.3million new TB
cases worldwide and 26% of new cases in the USA were attributed
to HIV infection.1 However, the incidence of TB in HIV patients
remains high in areas where TB is prevalent.2 The incidence of TB is
highest among patients with advanced HIV disease.3 Not only does
HIV increase the risk of reactivating a latent Mycobacterium
tuberculosis (MTB) infection, it also increases the risk of rapid TB
progression soon after infection or re-infection with MTB. Highly
active antiretroviral therapy (HAART) dramatically decreases the
incidence of opportunistic infections and death in patients with
advanced HIV infection, including those with TB.1 The immune
recovery associated with HAART results in dramatic clinical
beneﬁts, but this restoration of immunity may result in
immunopathological reactions and clinical deterioration when
HAART is initiated in patients with TB.4 Some patients experience
temporary exacerbation or worsening of symptoms, signs, and/or
radiographic manifestations of TB disease. This phenomenon is
termed ‘immune reconstitution inﬂammatory syndrome’ (IRIS).4
In this paper, we summarize the incidence, clinical presentations,* Corresponding author.
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therapeutic methods.
2. Methods
A literature search using the MEDLINE database for the period
January 1990 through October 2007 was performed to identify all
original studies on the immune reconstitution disease associated
with MTB infection. A full-text search using the following MeSH
terms ‘antiretroviral immune reconstitution syndrome’ or
‘immune paradoxical reaction’ or ‘immune reconstitution inﬂam-
matory syndrome’ or ‘immune reconstitution syndrome’ or
‘paradoxical worsening’ and ‘Mycobacterium tuberculosis’ or
‘tuberculosis’ was effected. A review of the bibliographies of
relevant articles was also conducted. Abstracts of all identiﬁed
articles were reviewed, and any relevant study, as determined on
the basis of the abstract, was reviewed in full. We identiﬁed 51
articles for review on the basis of the criteria stated below. Studies
were included if they were written in English, involved human
subjects, and reported data associated with MTB infection. Many
additional papers were identiﬁed from the references of other
published papers. Any studies that did not clearly meet these
criteria were reviewed by two investigators (SL and EN) who
reached a consensus regarding inclusion or exclusion of the article.
The investigators established inclusion and exclusion criteriases. Published by Elsevier Ltd. All rights reserved.
Table 1
Reported cases (N = 238) of TB-associated IRIS in the reviewed literature
Ref. Author Study Year Country No.
patients
Sex (M/F) Mean age Site pre-HAART Manifestation ART Steroids Interruption
HAART
Outcome
5 Hill CS 1994 USA 3 3/0 NS Pulmonary, CNS a-LN, c-LN, d-LN, i-LN,
pulmonary
NS No No S
6 Ramdas CR 1994 India 1 0/1 31 Pulmonary CNS None No No S
7 Narita PS 1998 USA 12 NS 35.8 NS c-LN, i-LN, pulmonary,
pleural effusion, ascites,
cutaneous
3 NRTI or 2
NRTI + 1 PI
Yes Yes (1
patient)
NS
8 Crump CR 1998 USA 1 1/0 35 None c-LN, pulmonary, CNS 2 NRTI + 1 PI Yes No S
9 John CR 1998 USA 1 1/0 44 i-LN, pulmonary i-LN, pulmonary 2 NRTI + 1 PI No No S
10 Chien CR 1998 USA 1 1/0 44 Pulmonary c-LN, i-LN 2 NRTI Yes No S
11 Kunimoto CR 1999 Canada 1 1/0 36 Pulmonary Pulmonary 2 NRTI + 1 PI Yes No S
12 Furrer CS 1999 Switzerland 3 NS NS Liver, GI,
pulmonary,
peritoneal,
urogenital
Hepatosplenomegaly, ia-LN,
pleural effusion, ascites,
epididymo-orchitis
2 NRTI + 1 PI Yes No S
13 French PS 2000 Australia 1 NS NS i-LN, pulmonary i-LN, pulmonary HAART NS NS S
14 Fishman RS 2000 USA 7 NS NS Pulmonary Pulmonary, pleural
effusion, i-LN, c-LN, ascites,
cutaneous
HAART NS NS NS
15 Orlovic CS 2001 South Africa 1 1/0 34 Pulmonary c-LN 2 NRTI + 1 PI No No S
16 Wendel CS 2001 USA 3 3/0 36.5 NS Subcutaneous, u-LN 3 NRTI No No S
17 Fernandes CS 2001 Brazil 3 2/1 33.7 c-LN, pulmonary i-LN, c-LN, in-LN 2 NRTI + 1
NNRTI
Yes No S
18 Navas CS 2002 Spain 6 AD AD NS Pulmonary, u-LN 2 NRTI + 1 PI Yes (2
patients)
Yes (4
patients)
S
19 Bottieau CR 2002 Belgium 1 0/1 32 Disseminated IAA, d-LN, ia-LN, pleural
effusion, ascites
2 NRTI + 1 PI Yes Yes S
20 Shelburne CS 2002 USA 2 1/1 36.5 Pulmonary
(1 patient)
ia-LN, GI 2 NRTI + 1 PI Yes No S
2 NRTI + 1
NNRTI
21 Wanchu CR 2002 India 1 NS NS i-LN c-LN, ia-LN 2 NRTI + 1 PI No No NS
22 Olalla RS 2002 Spain 9 7/2 31 NS Pulmonary, c-LN, a-LN,
CNS, IAA
HAART Yes (2
patients)
No 1 dieda
23 Guex CR 2002 Switzerland 1 1/0 30 GI GI 2 NRTI + 1 PI No No S
24 Eyer-Silva CR 2002 Brazil 1 1/0 34 c-LN CNS 2 NRTI + 1 PI Yes No S
25 Goldsack CR 2003 UK 1 1/0 41 None Pulmonary 2 NRTI + 1
NNRTI
No No S
26 de Lange CR 2003 Netherlands 1 1/0 33 i-LN a-LN, pulmonary, IAA 2 NRTI + 1 PI No No S
27 Ramos CR 2003 Spain 1 1/0 33 Disseminated c-LN, pulmonary 3 NRTI Yes No S
28 de Boer RS 2003 Netherlands 3 2/1 38 NS Extrapulmonary
(unspeciﬁed)
2 NRTI + PI (1
patient 2 PI)
NS NS NS
29 Vidal CR 2003 Brazil 1 NS NS CNS CNS HAART Yes No S
30 Breton RS 2004 France 16 11/5 33 Disseminated u-LN, IAA, GI, pulmonary,
cutaneous, parotitis
HAART Yes (6
patients)
Yes (7
patients)
S
31 Jehle CR 2004 Switzerland 1 1/0 58 Pulmonary Acute renal failure 2 NRTI + 1 PI Yes Yes S
32 Buckingham CS 2004 UK 2 NS NS i-LN, pulmonary i-LN, pulmonary, pleural
effusion
2 NRTI + 1
NNRTI
NS NS S
33 Breen RS 2004 UK 14 AD AD Disseminated Pulmonary, u-LN, pleural
effusion, ascites, CNS
HAART AD AD 3 died
34 Lawn CR 2004 UK 1 1/0 44 Pulmonary Pulmonary, hypercalcemia NNRTI + 2 PI Yes No S
35 Kumarasamy RS 2004 India 11 11/0 29 NS a-LN, c-LN, i-LN, in-LN 2 NRTI + 1
NNRTI
Yes (6
patients)
No S
36 Pedral-Sampaio PS 2004 Brazil 7 AD AD u-LN u-LN 2 NRTI + 1
NNRTI
AD AD AD
S.
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37 Patel PS 2004 India 11 AD AD NS NS 2 NRTI + 1
NNRTI
NS NS NS
38 Richardson CR 2005 UK 1 1/0 33 i-LN, pulmonary Pulmonary NS Yes No S
39 Miller CR 2005 UK 1 1/0 36 Pulmonary Pulmonary, i-LN 2 NRTI + 1
NNRTI
No No S
40 Swaminathan CR 2005 India 1 0/1 28 Pulmonary Pulmonary 2 NRTI + 1
NNRTI
Yes No S
41 Michailidis RS 2005 UK 14 10/4 35.2 NS u-LN, cutaneous, IAA,
subcutaneous
HAART Yes No NS
42 Verma CR 2006 USA 1 1/0 35 u-LN Granulomatous hepatitis 2 NRTI + 1 PI Yes No S
43 Manosuthi RS 2006 Thailand 21 18/3 34.2 NS Pulmonary, c-LN, ia-LN,
CNS, disseminated
2 NRTI + 1
NNRTI
Yes (11
patients)
No 2 died
44 Corti CR 2006 Argentina 1 1/0 37 Pulmonary CNS 2 NRTI + 1
NNRTI
Yes No S
45 Ferrand CR 2006 UK 1 1/0 52 Disseminated Hypercalcemia 2 NRTI + 1
NNRTI
No Yes S
46 Dautremer CR 2006 France 1 0/1 26 NS CNS HAART Yes Yes S
47 Narendran CR 2006 India 1 1/0 12 i-LN i-LN 2 NRTI + 1
NNRTI
Yes No S
48 Zampoli PS 2006 South Africa 4 3/1 24.5
months
Pulmonary, ia-LN Pulmonary, ascites, a-LN,
subcutaneous
2 NRTI +
NNRTI
No No 1 died
2 NRTI + PI
49 Rajeswaran RS 2006 UK 11 8/3 34.6 NS u-LN, i-LN, pulmonary,
pleural effusions,
pericardial effusion, ia-LN,
IAA, ascites, a-LN, sc-LN,
subcutaneous, CNS
HAART Yes No 1 died
50 Cailhol CR 2007 France 1 1/0 43 Pulmonary Cutaneous 2 NRTI + 1
NNRTI
No No S
51 Rathinam CR 2007 India 1 1/0 40 Pulmonary, ocular Pulmonary, ocular 2 NRTI + 1
NNRTI
Yes No S
52 Huyst CR 2007 Belgium 1 0/1 32 Granulomatous hepatitis d-LN, subcutaneous abscess 2 NRTI + 1 PI Yes Yes S
53 Park RS 2007 Korea 9 9/1 40.3 Pulmonary, CNS, orchitis Pulmonary, a-LN, CNS,
c-LN, i-LN, in-LN, epididymal
abscess
HAART NS NS NS
54 Lee CR 2007 China 1 1/0 54 Pulmonary CNS HAART Yes No S
55 Tuon CS 2007 Brazil 2 2/0 47 u-LN, pulmonary, CNS Granulomatous hepatitis,
spondylodiskitis, ia-LN
2 NRTI + 1 PI Yes No S
2 NRTI + 1
NNRTI
56 Manabe PS 2007 USA 4 AD 43 Disseminated, CNS Disseminated, CNS 2 NRTI + 1 PI Yes No S
57 Tansuphasawadikul RS 2007 Thailand 15 11/4 35 NS Pulmonary, disseminated 2 NRTI + 1
NNRTI
Yes (6
patients)
No S
58 Murdoch PS 2008 South Africa 9 2/7 31 Pulmonary,
disseminated,
abdominal, LN
Pulmonary, disseminated,
abdominal, LN
2 NRTI + 1
NNRTI
NS Yes (1
patients)
S
PS, prospective study; RS, retrospective study; CR, case report; CS, case series; M, male; F, female; NS, not stated; AD, aggregate data; HAART, highly active antiretroviral therapy; CNS, central nervous system; S, survived; NRTI,
nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; LN, lymphadenopathy; a-LN, axillary LN; c-LN, cervical LN; d-LN, diffuse LN; i-LN, intrathoracic LN; ia-LN,
intra-abdominal LN; in-LN, inguinal LN; sc-LN, supraclavicular LN; u-LN, unspeciﬁed LN; GI, gastrointestinal; IAA, intra-abdominal abscesses.
a Not because of IRIS, but due to hepatorenal syndrome.
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S. Leone et al. / International Journal of Infectious Diseases 14 (2010) e283–e291e286before reviewing abstracts and articles. The reported cases of TB-
associated IRIS in the reviewed literature are shown in Table 1.5–58
Finally, considering all reviewed articleswith available data, the
delta CD4 cell count and the delta viral load were calculated as the
differences between the CD4 cell count and the HIV plasma viral
loads (VL) at IRIS onset and at baseline. Linear correlations between
both delta CD4 cell count and viral load and the time on anti-TB
regimens and on HAART before IRIS onset were calculated. The
level of signiﬁcance was set at 0.05. All the analyses were
performed using SPSS for Windows 13.0 (SPSS Inc., Chicago, IL,
USA).
Before presenting the results of our review, some limitations
need to be discussed. Most of the revised original manuscripts had
a small population, were cases series or single case reports, and
were retrospective; no the recent proposal of a case deﬁnition is
still based on an experts’ consensus only.59
3. Epidemiology
Studies performed in Europe and the USA reported an incidence
of TB-associated IRIS varying between 11% and 45%.7,14,16,18,22,30,41
Breton et al. retrospectively studied antiretroviral-naive HIV-1-
infected patients who were treated subsequently for TB and HIV-1
infection and observed that 16 patients (43%) had an IRIS.30
Fishman et al. showed a transient worsening on radiography in 14/
31 (45%) AIDS patients receiving antiretroviral therapy (ART), and
of these, seven patients (23%) showed a severe worsening.14 Narita
et al. conducted a prospective study on 116 patients affected by TB
to determine the incidence of IRIS. It occurred in 36% (12/33) HIV-
positive patients with active TB receiving HAART, compared to 7%
of cases (2/28 patients) not receiving HAART and 2% of cases (1/55
patients) who were not HIV-infected.7 In a retrospective study of a
group of 33 HIV-infected patients with mycobacterial disease,
Olalla et al. registered nine cases of IRIS (27%), eight with MTB and
one with Mycobacterium avium complex (MAC). The annual
incidence of paradoxical responses during the ﬁrst two years of
the study was 20%, growing to 50% in the third year.22 In a study
performed in India by Furrer and Malinverni, 11/144 HIV-infected
TB individuals with a follow-up of 72 person-years developed IRIS
within 6 months of initiating HAART (incidence of IRIS 15.2 cases
per 100 patient-years).12 Finally, in an another observational
longitudinal study in India, Patel et al. observed a total of 11
patients affected by IRIS.37 However, paradoxical worsening of TB
after initiation of TB treatment has been reported in 2–23% of
treated TB patients without HIV infection.60 On this point, Breen
et al.33 showed that IRIS occurred in 5/50 (10%) HIV-negative
patients. In this group, disseminated TB was present in 4/5 (80%)
patients. The median time from starting TB treatment to IRIS was
87 days (range 23–157 days).
4. Pathogenesis
That IRIS is secondary to underlying immunological change is
widely accepted.61 Several studies indicate that CD4 T cell recovery
is sustained for 3–4 years in individuals with advanced HIV-1
infection who receive HAART.62,63 A reduction in plasma VL of
more than 90% occurs within the ﬁrst 1–2 weeks of HAART, and
associated increases in CD4 lymphocyte counts occur in two
principal phases.64 The initial rapid increase in the number of
circulating CD4 lymphocytes can usually be detected within 1–2
weeks of starting treatment and extends over the ﬁrst 2–3 months
of treatment. This increase largely represents a redistribution of
activated CD45+ R0+ memory cells previously sequestered in
lymphoid tissue and a reduction in apoptotic cell death.65,66 A
slower second phase of CD4 expansion occurs over subsequent
months and it may continues for years. This second phaserepresents expansion of naive CD45+ RA+ cells as thymic function
is restored and is largely responsible for the long-term sustained
rise in CD4 lymphocyte count. The rapid changes in CD4 numbers
and function would appear to have temporal correlation with TB-
associated IRIS. These phenomenamay provide the opportunity for
relevant pathogen-speciﬁc cells to gain access to sites of infection
and engage in the host inﬂammatory response to foreign antigen.4
Bourgarit et al. conducted a prospective, multicenter study on 19
consecutively enrolled patients with HIV-TB co-infection and
reported that an acute exacerbation of mycobacteria-speciﬁc Th1
response immediately after the HIV infection control by HAART
causes IRIS; these ﬁndings were independent of the CD4
lymphocyte count, the VL, and the time of HAART initiation.67
Such reactions do not require the presence of viable organisms
because they can occur after successful TB treatment. Acid-fast
bacilli identiﬁed in IRIS events are often not found to be viable. In
certain TB-associated IRIS patients, rapid restoration of the
cutaneous tuberculin reaction has been observed.7 The immuno-
pathogenicmechanisms causing IRIS seem to be determined by the
pathogen.68 For example, several lines of evidence indicate that
mycobacterial IRIS results from a delayed-type hypersensitivity
(DTH) response tomycobacterial antigens. Granulomatous inﬂam-
mation and tissue necrosis are typical of DTH responses, and two
cases of IRIS accompanied by hypercalcemia have been reported to
be associated with TB.34,46,69 Hypercalcemia is a recognized
manifestation of other granulomatous lung diseases, including
sarcoidosis, and fungal infections. If hypercalcemia plays a direct
role in the pathogenesis of IRIS is not clear. Finally, there are
disease susceptibility genes that may be associated with the
occurrence of IRIS. On this point, Price et al. investigated
polymorphisms in cytokine genes to determine whether the
encoded cytokines affect the IRIS pathogenesis. The authors
observed that TNFA-308*2 was slightly more common in patients
with herpesvirus-associated IRIS (p = 0.042 relative to patients
without IRIS) and it was not present in any patients who had
experienced IRIS associated with mycobacterial infection
(p = 0.035 relative to patients without IRIS and p = 0.015 relative
to seronegative controls). IRIS associated with mycobacterial
infection occurred only in individuals who were homozygous for
TNFA-308*1 (100% carriage), and non-carriage of IL6-174*C was
more common than in patients without IRIS (relative risk = 3.0;
p = 0.014).70 However, future studies are needed to elucidate these
points in the pathogenesis of IRIS.
5. Risk factors
Several risk factors for TB-associated IRIS have been identiﬁed.
First, considering the available data in the literature, we assessed
the time interval between initiation of TB therapy and starting
HAART. In a systematic review of 86 cases, Lawn et al. showed that
the median duration of anti-TB treatment before the onset of IRIS
was 8weeks (interquartile range (IQR) 5.5–11.5weeks; range 2–48
weeks), whereas the median duration of HAART was only 4 weeks
(IQR 2–10 weeks; range 1–44 weeks).4 Manosuthi et al., in a
retrospective study, described 21 HIV-positive TB patients with
onset of TB-associated IRIS 32 days after initiating HAART. Of these,
15 (71.4%) patients developed IRIS within the ﬁrst 2 months of
HAART.43 In a report by Tansuphasawadikul et al., the occurrence
of IRIS was associated with a shorter time between anti-TB
treatment and ART (31 days versus 90 days; p < 0.05).57 Navas
et al. showed that the median time that elapsed between the
initiation of anti-TB therapy and the initiation of HAART was 22
days for patients who developed IRIS compared to 110 days for
patients without IRIS. All patients with paradoxical responses had
initiated HAART within the ﬁrst 2 months of anti-TB therapy, in
contrast with only two of the 11 patients who did not have the
S. Leone et al. / International Journal of Infectious Diseases 14 (2010) e283–e291 e287reactions (100% versus 18%, respectively; p = 0.002).18 However, in
the study of Michailidis et al., there was no signiﬁcant difference
between the median time that elapsed between the initiation of
anti-TB therapy and the initiation of HAART in patients with IRIS
compared with the non-IRIS group (0.8 versus 0.6 months;
p = 0.730).41 Finally, considering the available data in the
literature, we determined the time interval between the initiation
of antiretroviral agents and/or anti-TB therapy and the occurrence
of IRIS to be 4 weeks (IQR 2–8 weeks; range 0.5–44 weeks) and 8
weeks (IQR 4–12 weeks; range 1–80 weeks), respectively.
Secondly, according to the literature, a baseline CD4 T-cell
count below 50 cells/ml and a VL of>105 log10/ml, associated with
a good viro-immunological response to HAART, are major risk
factors for IRIS. Shelburne et al., in a retrospective chart review,
observed that patients with IRIS were more likely to have a more
rapid initial fall in HIV-RNA level in response to HAART
(p < 0.001).71 Breton et al., found that after 1 month of HAART,
the increase in CD4 cell percentage (odds ratio (OR) 1.34; 95%
conﬁdence interval (CI) 1.08–1.66) and the increase in the CD4/
CD8 ratio (OR 1.55; 95% CI 1.06–2.26) were the two variables
independently associatedwith IRIS occurrence.30 In a retrospective
study,Michailidis et al. observed that themedian baseline CD4, but
not the VL, for patients in the IRIS group was signiﬁcantly lower
than for those in the non-IRIS group (80 versus 139 cells/ml;
p = 0.05). Ina case-control studyconducted inSouthAfrica,Murdoch
et al. observed that high baseline CD4 cell count was a protective
factor for IRIS occurrence (hazard ratio (HR) 0.72 per 50 cells/mlFigure 1. Original manuscripts on TB-related IRIS events: correlation between the
deltaCD4cell countand thetimeonHAARToronananti-TBregimenbefore IRISonset.increase) in multivariate analyses.58 Similar results were observed
byOlalla et al.,who showeda signiﬁcantdifferencebetween theCD4
cell count 6months after diagnosis of TB (221 versus 127 cells/ml in
patients without IRIS and with IRIS, respectively; p = 0.048).22 In a
case-control study on IRIS byManabe et al., the development of IRIS
was independently associated with the use of a boosted protease
inhibitor (PI; OR 7.41; p = 0.006), with a CD4 of< 100/ml nadir (OR
6.2; p < 0.001), and with a 2.5 log HIV-RNA decrease at IRIS
occurrence compared with baseline levels.56
Third, other potential risk factors for IRIS occurrence are MTB
extrapulmonary localization or disseminated disease. By multi-
variate analysis, extrapulmonary TB was an independent risk
factor for IRIS (OR 8.225; 95% CI 1.785–37.911; p = 0.007).56
Finally, considering the cumulative data reported in Table 1, the
median CD4 lymphocyte count at baseline and at IRIS onset were
55  106 cells/l (IQR 30–103; range 8–317) and 170.5  106 cells/l
(IQR 110–267; range 66–422), respectively, and the VL at baseline
and IRIS onset were 5.6 log10 copies/ml (IQR 5.1–5.8; range 3–6.1)
and 2.6 log10 copies/ml (IQR 2.6–3.7; range 1.7–4.4), respectively.
Considering all original articles with available data on the viro-
immunological count of patients at the initiation of an anti-TB
regimen and at IRIS onset, graphical scatter plots were designed.
Linear correlations between time on anti-TB regimens and on
HAART before IRIS onset and both delta CD4 cell count and delta VL
were calculated. No signiﬁcant correlations were seen between
immunological and virological parameters and time of initiation of
any drugs before IRIS onset (Figures 1 and 2).Figure 2. Original manuscripts on TB-related IRIS events: correlation between the
delta HIV-RNA and the time on HAART or on an anti-TB regimen before IRIS onset.
S. Leone et al. / International Journal of Infectious Diseases 14 (2010) e283–e291e2885.1. Case deﬁnition and diagnosis
IRIS is mainly a clinical diagnosis, particularly when IRIS
develops shortly after the initiation of anti-TB treatment and
HAART. Laboratory tests may not be useful for differentiating
between TB IRIS and anti-TB treatment failure, and the differential
diagnoses of TB-associated IRIS need to be evaluated. Particularly,
clinicians should exclude the occurrence of serious side effects of
HAART (e.g., drug fevers), TB infection not responding to treatment
due to resistance or poor adherence to treatment, and other HIV- or
non-HIV-related infections and tumors.72 To help clinicians in this
challenging diagnosis, different case deﬁnitions have been
proposed in the past. In 2004, French et al. proposed different
criteria for IRIS diagnosis in HIV patients on HAART, requiring two
major criteria or one major criterion and two minor criteria. Major
criteria were: (1) atypical presentation of opportunistic infections
or tumors in patients responding to antiretroviral therapy and (2)
>1 log10 HIV-RNA copy decrease in plasma. Minor criteria were:
(1) increased blood CD4 T-cell count after HAART, (2) increased
speciﬁc immune response to relevant pathogens, and (3)
spontaneous resolution of disease without antimicrobials or
chemotherapy with continuation of antiretroviral therapy.68 In
2006, two other proposals of case deﬁnitions were published.
Shelburne et al., proposed a case deﬁnition including clinical,
immunological, and virological parameters.73 Colebunders et al.
proposed a case deﬁnition of suspected or conﬁrmed IRIS diagnosis
based on clinical, viro-immunological, and radiological criteria.72
Robertson et al. proposed a clinical scoring system, also including
the use of PIs.74 Zhou et al. showed that the predictive model
developed by Robertson et al. had a very low performance in Asian
populations.75 Similarly all other case deﬁnitions were wealthy-
country oriented and needed a high technology capacity other than
human resources. Conversely, themajor requirement for aworking
case deﬁnition of IRIS is the real applicability in low-resource
settings. The International Network for the Study of HIV-associated
IRIS invited around 100 researchers from 16 countries to Kampala,
Uganda, in November 2006, to provide consensus IRIS case
deﬁnitions suitable for high-income and low-resource countries.56
Meintjes et al. published the consensus-based case deﬁnitions for
TB-associated IRIS in 2008. First, paradoxical TB-associated IRIS: a
paradoxical reaction in patients who have recently started HAART
already on a favorable TB treatment. Second, antiretroviral-
associated TB: a new TB diagnosis fulﬁlling World Health
Organization criteria with inﬂammatory presentation in patients
who are already on HAART. Third, unmasking TB-associated IRIS: a
new TB diagnosis with inﬂammatory presentation complicated
and unmasked by paradoxical reaction in patients who are already
on HAART. Meintjes et al. considered that the omission of
virological, immunological, and radiological laboratory parameters
would not substantially compromise case deﬁnitions for TB-
associated IRIS and that they could be used by clinicians and
researchers in a variety of settings to promote standardization and
comparability of data.59
5.2. Clinical manifestations
The IRIS in patients with TB may have protean manifestations,
most commonly fever, nodal enlargement, and worsening
pulmonary inﬁltrates observed on a chest radiograph, with or
without recurrent respiratory symptoms. Clinical data available in
the speciﬁc literature are summarized in Table 1. Localized
lymphadenopathy was present in 95 (45.2%) cases (cervical
n = 37; intra-thoracic n = 26; intra-abdominal n = 15; axillary
n = 11; inguinal n = 3; diffuse n = 2; supraclavicular n = 1), followed
by pulmonary involvement in 51 (24.3%) patients, and central
nervous system manifestations, as meningitis or abscesses, in 10(4.8%). Serositis was commonly described; in particular, pleural
effusion, ascites, and pericardial effusion were reported in 11
(5.2%), 7 (3.3%), and 1 (0.5%) case, respectively. Cutaneous and
subcutaneous involvement was reported in 6 (2.8%) and 11 (5.2%)
patients, respectively. Overall, gastrointestinal involvement,
including ileo-cecal perforation, and intra-abdominal abscesses
and hepatitis were reported in 12 (5.7%) patients. Rare manifesta-
tions were acute renal failure, epididymo-orchitis, hypercalcemia,
and ocular involvement. However, although some manifestations
of TB-associated IRISwere life-threatening, only seven deathswere
reported overall. As reported in Table 1, the localization of the
more common clinical manifestations of IRIS usually reﬂect the
initial sites of the TB presentation before starting HAART. However,
in a few reports, IRIS clinical manifestations are characterized by
the involvement of anatomical sites not previously affected by
TB.6,10,15,20,24,31,50,52 This ﬁnding suggests that such a paradoxical
reaction is triggered by various combinations of different factors
and not only by the presence of microorganisms.
6. Therapy
Themanagement of IRIS has not beenwell studied, butmild-to-
moderate reactions can bemanaged with reassurance and perhaps
non-steroidal anti-inﬂammatory agents. The cases of life-threa-
tening forms of TB-associated IRIS can be managed with
corticosteroids or temporary discontinuation of ART.76 The use
of systemic corticosteroids has been most widely employed in TB-
associated IRIS, perhaps because of the previously accepted role for
immune modulation in some forms of TB.7,10 The method of
delivery, dosing, or duration of therapy is not currently well
established. Short-term prednisone administration, in doses of
0.5 mg/kg daily for 2–4 weeks, appears to be well tolerated and
safe when given to individuals maintained on stable HAART
regimens.77 In a double-blind placebo-controlled randomized
clinical trial (RCT), Meintjes et al. showed that prednisone
(1.5 mg/kg/day for 2 weeks, followed by 0.75 mg/kg/day for 2
weeks) reduced the need for hospitalization and procedures, and
resulted in symptom improvement without an excess of corticos-
teroid side effects or severe infections.78 However, given that the
inﬂammatory response is amarker for immune restoration, HAART
should be continued in all cases where the inﬂammatory reaction
does not immediately threaten mortality or result in signiﬁcant
morbidity.79 Surgical intervention may occasionally be required
for complications such as organ rupture or for drainage proce-
dures.4 Finally, to reduce the incidence of IRIS, it has been
suggested that bacillary load should be sufﬁciently reduced prior
to the start of HAART by respecting a lengthy enough interval
between the start of anti-TB treatment and HAART. The ﬁnding
that all patients who developed TB-associated IRIS received HAART
within 2months of starting anti-TB therapy suggests that itmay be
prudent towait to begin speciﬁc anti-HIV therapy in these patients,
if their clinical situation allows.18 Recently, Schiffer and Sterling
conducted a decision analysis in hypothetical cohorts of 1000
patients in which HAART was initiated during the ﬁrst 2 months of
TB therapy (early) or during months 2 through 6 of TB therapy
(deferred) or was withheld until after TB therapy (no-HAART).
Outcomes assessed were 1-year mortality and the combined
outcome of 1-year mortality, new AIDS-deﬁning illness, severe
IRIS, and severe drug toxicity.80 More recently, Abdool Karim et al.
conducted a prospective, open-label RCT to determine optimal
timing of HAART initiation in relation to TB treatment. Patients
were randomized to the integrated TB/HIV treatment arm (HAART
initiation during TB treatment) or the sequential treatment arm
(HAART initiation upon TB treatment completion). At intent-to-
treat analysis, the mortality rates were signiﬁcantly lower in the
integrated treatment arm regardless of CD4 count; for participants
S. Leone et al. / International Journal of Infectious Diseases 14 (2010) e283–e291 e289with CD4 counts <201 cells/ml, the HR was 0.54 (p = 0.044), while
for CD4 counts from 201 to 500 cells/ml, the HR was 0.08
(p = 0.023).81 Some experts would base the decision of when to
start HAART on the immunological status of the patient. To reduce
the occurrence of IRIS in patients with a CD4 <100/ml, HAART
should be started after2weeks of TB treatment. For persons with
a CD4 cell count of 100–200/ml, some experts would delay HAART
until the end of the 2-month intensive phase of anti-TB treatment.
In those with a sustained CD4 cell count >200/ml, HAART could be
started during the anti-TB maintenance phase and for those with a
CD4 cell count >350 cells/ml, after ﬁnishing anti-TB treatment.82
7. Conclusions
TB and HIV disease have been inextricably bound together from
the early years of the HIV/AIDS epidemic. In high-income
countries, the rate of new MTB and HIV infections has slowed,
and the numbers of individuals living with HIV infection have
increased. In contrast, in resource-limited countries, where high
rates of MTB infection already exist, both the incidences and the
prevalence of HIV/AIDS and TB have continued to increase
dramatically.83 In this population, IRIS can be a potential
complication following the initiation of HAART. Among the few
case-control studies on HIV and non-HIV-infected patients, the
incidence of IRIS has been found to be 28–36% and 7–10%,
respectively.7,33 Furthermore, other studies comparing the IRIS and
non-IRIS group have demonstrated that extrapulmonary TB, a
lower CD4 cell count at baseline, an increase in the CD4 cell
percentage and in the ratio of CD4/CD8 cells 1 month after
initiation of HAART, and a greater decrease in the VL after
introduction of HAART are variables associated with IRIS
occurrence.18,30,41,43 Nevertheless, our systematic review failed
to ﬁnd a linear correlation between the time on TB regimen and on
HAART and the viro-immunological parameters (delta CD4 cell
count and VL).Moreover, the role of themycobacterial antigen load
in the pathogenesis of IRIS is an interesting aspect and is worthy of
further studies.61
Diagnosis and timing of HAART initiation are controversial
issues. Firstly, the criteria for a diagnosis of IRIS proposed by French
et al., Shelburne et al., or Colebunders et al. are not useful in
resource-poor settings because they require the determination of
viro-immunological parameters, or of the response to mycobac-
terial antigens, or of radiological ﬁndings.68,72,73 Recently, the
International Network for the Study of HIV-associated IRIS
developed case deﬁnitions for high-income and resource-limited
settings that focused speciﬁcally on clinical manifestations of TB-
associated IRIS only.59 The use of this consensus-based standar-
dized case deﬁnition will help to provide greater insight into the
incidence, clinical manifestations, risk factors, and impact of TB-
associated IRIS, ultimately leading to better prevention and
management strategies. Nevertheless, the correct diagnosis of
active TB before ART initiation is the priority goal in low-income
countries, and international efforts are needed to strengthen both
laboratory and clinical capacity in TB diagnosis and treatment.
New diagnostic tools such as transrenal DNA for the detection of
small extracellular urinary DNA fragments and cheap immune
speciﬁc technology for use in the ﬁeld, among others, are strongly
advocated in the next years to provide early, prompt identiﬁcation
of TB cases.84,85 Secondly, the most frequent interval between
starting HAART and the occurrence of IRIS is 30–60 days, however
delayed IRIS has been described.50 Research is needed to determine
the relative merits of delaying initiation of ART to permit full
culture-based investigation for TB versus starting ART without
delay if there is no initial evidence of TB. Finally, more recently,
Rebe et al., in a prospective study in South Africa, observed that the
rates of TB drug resistance appear to be higher among patientspresenting with suspected TB-associated IRIS compared with
background MDR prevalence. These ﬁndings suggest that TB drug
resistance should be excluded in all TB-associated suspects and
corticosteroids should be used with caution in patients with
presumed TB-IRIS until this result is known.86
In conclusion, prospective studies performed in countries with
high prevalence of HIV/MTB co-infection are needed as future
works: (1) to identify a real comprehensive deﬁnition of IRIS, (2) to
identify underlying mechanisms independently related to IRIS
occurrence, (3) to identify exacerbating risk factors, (4) to identify
the optimum time of HAART in a few selected conditions, and (5) to
build therapeutic strategies to successfully treat IRIS, if needed.
Conﬂict of interest: No conﬂict of interest to declare.
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